{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:07:40Z","timestamp":1790852860712,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1097\/01.qco.0000200290.99790.72","type":"journal-article","created":{"date-parts":[[2005,12,21]],"date-time":"2005-12-21T09:02:29Z","timestamp":1135155749000},"page":"33-38","source":"Crossref","is-referenced-by-count":26,"title":["Strategies to prevent mother-to-child transmission of HIV"],"prefix":"10.1097","volume":"19","author":[{"given":"James","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20210211","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/427287","article-title":"Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R3-7-20210211","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/00126334-200408150-00011","article-title":"Decline in perinatal HIV transmission in New York State (1997-2000)","volume":"36","author":"Wade","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-7-20210211","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00126334-200501010-00016","article-title":"Risk factors for in utero and intrapartum transmission of HIV","volume":"38","author":"Magder","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-7-20210211","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archpedi.158.5.422","article-title":"Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 Serosurvey of childbearing women","volume":"158","author":"Mofenson","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R6-7-20210211","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001432-200406000-00013","article-title":"Prevention of mother-to-child transmission of HIV infection","volume":"17","author":"Thorne","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"R7-7-20210211","first-page":"1119","article-title":"ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations.","volume":"104","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R8-7-20210211","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-143-1-200507050-00009","article-title":"Prenatal screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force","volume":"143","author":"Chou","year":"2005","journal-title":"Ann Intern Med"},{"key":"R9-7-20210211","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/apc.2005.19.247","article-title":"Achieving universal HIV screening in prenatal care in the United States: provider persistence pays off","volume":"19","author":"Anderson","year":"2005","journal-title":"AIDS Patient Care STDS"},{"key":"R10-7-20210211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jama.292.2.219","article-title":"Rapid HIV-1 testing during labor: a multicenter study","volume":"292","author":"Bulterys","year":"2004","journal-title":"JAMA"},{"key":"R11-7-20210211","first-page":"1083","article-title":"Introduction of routine HIV testing in prenatal care-Botswana, 2004.","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R15-7-20210211","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1471-0528.2005.00716.x","article-title":"Preventing mother-to-child transmission of HIV: successes and challenges","volume":"112","author":"McIntyre","year":"2005","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"R16-7-20210211","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajog.2004.05.061","article-title":"Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy","volume":"191","author":"Watts","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R17-7-20210211","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archinte.162.3.355","article-title":"Periconceptional exposure to efavirenz and neural tube defects","volume":"162","author":"De Santis","year":"2002","journal-title":"Arch Intern Med"},{"key":"R18-7-20210211","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002030-200201250-00025","article-title":"Myelomeningocele in a child with intrauterine exposure to efavirenz","volume":"16","author":"Fundaro","year":"2002","journal-title":"AIDS"},{"key":"R19-7-20210211","first-page":"17","article-title":"Efavirenz reclassified as FDA pregnancy category D","volume":"17","author":"Mofenson","year":"2005","journal-title":"AIDS Clin Care"},{"key":"R20-7-20210211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/01.qai.0000139398.38236.4d","article-title":"Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy","volume":"38","author":"Tuomala","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-7-20210211","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.qai.0000174651.40782.95","article-title":"Protease inhibitor use in 233 pregnancies","volume":"40","author":"Morris","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-7-20210211","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ajog.2003.07.018","article-title":"Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316","volume":"190","author":"Watts","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R24-7-20210211","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00002030-200411190-00019","article-title":"Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe","volume":"18","author":"Thorne","year":"2004","journal-title":"AIDS"},{"key":"R25-7-20210211","first-page":"2021","article-title":"Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997\u20132003: safe, effective and with few side effects [in Dutch]","volume":"148","author":"Tempelman","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R26-7-20210211","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000168973.59466.14","article-title":"Nelfinavir and nevirapine side effects during pregnancy","volume":"19","author":"Timmermans","year":"2005","journal-title":"AIDS"},{"key":"R31-7-20210211","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11908-005-0014-0","article-title":"Progress and emerging challenges in preventing mother-to-child transmission","volume":"7","author":"Chersich","year":"2005","journal-title":"Curr Infect Dis Rep"},{"key":"R32-7-20210211","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1086\/431606","article-title":"Appropriate use of nevirapine for long-term therapy","volume":"192","author":"Leith","year":"2005","journal-title":"J Infect Dis"},{"key":"R34-7-20210211","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00126334-200407010-00002","article-title":"Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG","volume":"36","author":"Hitti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-7-20210211","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(99)80008-7","article-title":"Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial","volume":"354","author":"Guay","year":"1999","journal-title":"Lancet"},{"key":"R39-7-20210211","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1126\/science.306.5705.2168","article-title":"HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy","volume":"306","author":"Cohen","year":"2004","journal-title":"Science"},{"key":"R41-7-20210211","first-page":"289","article-title":"PMTCT from research to reality\u2013results from a routine service","volume":"94","author":"Sherman","year":"2004","journal-title":"S Afr Med J"},{"key":"R43-7-20210211","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1097\/00002030-200409030-00018","article-title":"Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation","volume":"18","author":"Quaghebeur","year":"2004","journal-title":"AIDS"},{"key":"R44-7-20210211","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00002030-200301030-00009","article-title":"Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya","volume":"17","author":"Kiarie","year":"2003","journal-title":"AIDS"},{"key":"R45-7-20210211","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-200307250-00010","article-title":"Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine","volume":"17","author":"Stringer","year":"2003","journal-title":"AIDS"},{"key":"R46-7-20210211","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/00002030-200404090-00012","article-title":"Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings","volume":"18","author":"Stringer","year":"2004","journal-title":"AIDS"},{"key":"R47-7-20210211","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00126334-200311010-00003","article-title":"Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon","volume":"34","author":"Ayouba","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R48-7-20210211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000148530.66587.7c","article-title":"Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda","volume":"39","author":"Kagaayi","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R49-7-20210211","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00126334-200502010-00013","article-title":"Evaluating programs to prevent mother-to-child HIV transmission in two large Bangkok hospitals, 1999\u20132001","volume":"38","author":"Teeraratkul","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R50-7-20210211","first-page":"796","article-title":"The efficacy-effectiveness gap in PMTCT","volume":"94","author":"Delva","year":"2004","journal-title":"S Afr Med J"},{"key":"R51-7-20210211","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/01.aids.0000180102.88511.7d","article-title":"Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia","volume":"19","author":"Stringer","year":"2005","journal-title":"AIDS"},{"key":"R53-7-20210211","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa033500","article-title":"Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand","volume":"351","author":"Lallemant","year":"2004","journal-title":"N Engl J Med"},{"key":"R54-7-20210211","first-page":"309","article-title":"Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission","volume":"19","author":"Dabis","year":"2005","journal-title":"AIDS"},{"key":"R56-7-20210211","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.aids.0000180100.42770.a7","article-title":"A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers","volume":"19","author":"Gray","year":"2005","journal-title":"AIDS"},{"key":"R57-7-20210211","first-page":"283","article-title":"Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1","volume":"38","author":"Cressey","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R58-7-20210211","first-page":"S86","article-title":"HIV-1 variants with diverse nevirapine resistance mutations emerge rapidly after single dose nevirapine: HIVNET 012","volume":"8","author":"Eshleman","year":"2003","journal-title":"Antiviral Therapy"},{"key":"R59-7-20210211","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00126334-200402010-00004","article-title":"Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)","volume":"35","author":"Eshleman","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R60-7-20210211","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/0889222041217518","article-title":"Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012","volume":"20","author":"Eshleman","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R62-7-20210211","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.qai.0000174656.71276.d6","article-title":"Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012","volume":"40","author":"Eshleman","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R63-7-20210211","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/444424","article-title":"Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine","volume":"192","author":"Lee","year":"2005","journal-title":"J Infect Dis"},{"key":"R65-7-20210211","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":"Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy","volume":"351","author":"Jourdain","year":"2004","journal-title":"N Engl J Med"},{"key":"R66-7-20210211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002030-200501030-00007","article-title":"Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy","volume":"19","author":"Lyons","year":"2005","journal-title":"AIDS"},{"key":"R67-7-20210211","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/00002030-200110190-00006","article-title":"Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)","volume":"15","author":"Eshleman","year":"2001","journal-title":"AIDS"},{"key":"R68-7-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/430745","article-title":"Single-dose nevirapine and drug resistance: the more you look, the more you find","volume":"192","author":"Hammer","year":"2005","journal-title":"J Infect Dis"},{"key":"R69-7-20210211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"R71-7-20210211","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"}],"container-title":["Current Opinion in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000658-200601000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T02:28:36Z","timestamp":1618280916000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001432-200602000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.qco.0000200290.99790.72","relation":{},"ISSN":["0951-7375"],"issn-type":[{"value":"0951-7375","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}